Summary
Boston Scientific Corporation (BSX) has announced the completion of its acquisition of Axonics, Inc., a medical technology company specializing in urinary and bowel dysfunction devices. The deal was finalized on November 15, 2024, for $71 in cash per share, representing an equity value of $3.7 billion and an enterprise value of $3.3 billion after accounting for acquired cash and investments. This strategic acquisition is expected to have a minimal impact on adjusted earnings per share (EPS) in 2024 and 2025, becoming accretive thereafter. On a GAAP basis, the transaction is anticipated to be less accretive or more dilutive due to amortization expenses and acquisition-related costs. Investors should note the forward-looking statements and the cautionary notes regarding potential risks and uncertainties that could affect actual results.
Key Highlights
- 1Boston Scientific has successfully acquired Axonics, Inc. for $71 per share in cash.
- 2The total equity value of the transaction is $3.7 billion, with an enterprise value of $3.3 billion.
- 3Axonics is a developer of medical devices for urinary and bowel dysfunction.
- 4The acquisition is expected to be immaterial to adjusted EPS in 2024 and 2025, becoming accretive thereafter.
- 5GAAP EPS is expected to be less accretive or more dilutive due to amortization and acquisition-related charges.
- 6The transaction is officially closed as of November 15, 2024.